【中美医学合作新典范：中国方案改写全球指南，美国患者跨洋求医】四川大学华西肺癌中心主任周清华教授带领团队，将晚期“不可手术”肺癌患者的生存率提升至30%以上，达到国际平均水平的3倍。这一来自中国的真实世界临床数据，直接推动了国际肺癌研究协会（IASLC）指南的修订。#健康无国界#

近日，4位美国患者专程飞抵中国，请周教授主刀高难度手术。这不仅体现了美国患者对中国顶尖医疗能力的高度信任，更成为中美医学深度合作的生动缩影——从临床试验数据共享，到诊疗标准互鉴，再到跨国生命接力，每一步都离不开双方的开放与协作。

在全球化面临挑战的当下，医学始终是最能跨越分歧的共同语言。唯有坚持科学无国界、携手攻克难题，才能为全球患者赢得更多生机。#中美医学合作# #健康#

Professor Zhou Qinghua, director of the West China Lung Cancer Center and a globally recognized authority in oncology, is bridging Chinese clinical mastery and international standards. By achieving survival rates of over 30% for advanced-stage cases once deemed "inoperable" – triple the international average – his data directly influenced the revision of the International Association for the Study of Lung Cancer (IASLC) guidelines. This ensures that Chinese clinical innovation now informs the global gold standard of care.

Professor Zhou's clinical achievements have built a reputation that transcends borders. Recently, four American patients traveled to China specifically to receive his intervention in high-stakes surgeries, reflecting profound trust in his ability to tackle complex challenges. In a volatile world, medicine is common ground. Prioritizing health over friction builds a better, evidence-based future. Cooperation is the only way to save lives.